A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Brigham and Women's Hospital
VM Oncology, LLC
University of Texas Southwestern Medical Center
Vanderbilt-Ingram Cancer Center
University of Pittsburgh
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello